Skip to main content

Generate Biomedicines

Category: AI in Healthcare

A clinical-stage biotechnology company utilizing generative AI to design and create novel protein therapeutics on demand, moving beyond traditional drug discovery to programmable drug generation. Generate Biomedicines was founded in 2018. The company is led by Michael Nally. Based in Somerville, USA. Team size: 400+. Total funding raised: $693.0M. Latest round: Strategic Investment (Apr 2024). Key investors include ["Flagship Pioneering","Fidelity Management & Research Company","NVentures (NVIDIA)","T. Rowe Price","Mubadala Investment Company","Samsung Life Science Fund","Arch Venture Partners"].

Founded
2018
Headquarters
Somerville, USA
Team size
400+
Total funding
$693.0M

Value proposition

Drastically reduces the time and cost of drug development by using machine learning to 'generate' optimized proteins with specific functions, rather than screening existing natural libraries.

Products and solutions

["The Generate Platform (Generative Biology AI engine)","GB-0669: A Phase 1 monoclonal antibody targeting a highly conserved region of the SARS-CoV-2 spike protein.","GB-0895: A potent anti-TSLP antibody for the treatment of severe asthma (entering clinical trials).","Multi-target oncology pipeline (including bispecifics and T-cell engagers).","Infectious disease and immunology programs."]

Unique value

The company pioneered 'Generative Biology,' a shift from searching for drugs in nature to computationally designing proteins from scratch (de novo) to meet specific therapeutic profiles.

Target customer

Global pharmaceutical companies for R&D collaborations, and the broader healthcare market for proprietary therapeutic treatments.

Industries served

["Biotechnology","Pharmaceuticals","Artificial Intelligence","Healthcare"]

Technology advantage

A closed-loop system that integrates proprietary machine learning models with high-throughput experimental 'wet labs' and Cryo-EM, allowing the AI to learn from its own biological validations in real-time.

How they differentiate

Focuses on 'Generative Biology'—designing de novo proteins from scratch rather than screening existing libraries. It utilizes a closed-loop system where proprietary AI models are integrated with high-throughput 'wet labs' and Cryo-EM to validate and refine biological designs in real-time.

Main competitors

["Absci","Recursion Pharmaceuticals","Isomorphic Labs","Insilico Medicine"]

Key partnerships

["Amgen: A multi-target collaboration worth up to $1.9 billion to discover and develop protein therapeutics.","MD Anderson Cancer Center: Strategic collaboration to accelerate the development of oncology therapeutics.","Sanofi: Collaboration focused on the development of first-in-class and best-in-class antibodies.","NVIDIA (NVentures): Strategic investment and technical collaboration for AI infrastructure optimization."]

Notable customers

["Amgen","Sanofi","MD Anderson Cancer Center"]

Major milestones

["Launched out of Flagship Pioneering in 2018","Entered $1.9B multi-target collaboration with Amgen in 2022","Initiated Phase 1 clinical trial for GB-0669 (COVID-19 antibody) in 2023","Raised $273M Series C, the largest biotech Series C of 2023","Reported preparation for an Initial Public Offering (IPO) in late 2024/2025"]

Growth metrics

Scaled to over 400 employees; advanced two programs into clinical/pre-clinical stages; secured over $2B in potential milestone payments through partnerships.

Market positioning

Clinical-stage pioneer and category leader in generative AI-driven protein therapeutics.

Geographic focus

Global, with primary operations in North America (Somerville, MA) and strategic partnerships in Europe and Asia.

Patents and IP

Holds a robust IP portfolio including patents for generative AI methods for protein design, specific molecular compositions for COVID-19 antibodies, and proprietary structural biology techniques (e.g., US Patent 11,664,103).

About Michael Nally

Michael Nally has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Generate Biomedicines in 2021, he spent 18 years at Merck, where he served as Executive Vice President and Chief Marketing Officer of the Human Health division. He also led Merck's $10B+ Global Vaccines business as President and managed the company's operations in the UK and Ireland. He is currently a CEO-Partner at Flagship Pioneering.

Official website: